This article summarizes an evidence report for the California Technology Assessment Forum about the comparative effectiveness and value of surgical, device, and new drug vs lifestyle, diet, and existing drug treatment of obesity.
Article InformationCorresponding Author: Daniel A. Ollendorf, PhD, Institute for Clinical and Economic Review, One State Street, 10th Floor, Boston, MA 02109 (email@example.com).
Published Online: January 4, 2016. doi:10.1001/jamainternmed.2015.7189.
Conflict of Interest Disclosures: Dr Cameron has served on an advisory board for Eli Lilly & Co. No other disclosures are reported.
Funding/Support: The CTAF is a program of the Institute for Clinical and Economic Review and is supported by grants from the BlueShield of California Foundation, the California HealthCare Foundation, and the Laura and John Arnold Foundation.
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: Karen Shore, PhD, Matthew Seidner, Patricia Synnott, MALD, MS, and Anne Loos, MS, of the Institute for Clinical and Economic Review contributed to the development of this manuscript.